Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Amprius Technologies finds itself at an awkward junction this week: a fresh analyst initiation at a Buy, a stock down 10% on the week, and options markets that have turned more bullish than at any point in the past year.
The most notable development is the timing of Canaccord Genuity's initiation. George Gianarikas began coverage on October 14 with a Buy rating and a $14 target. That lands at a 63% premium to Tuesday's close of $8.56, yet it is the most conservative target on the Street by some margin. HC Wainwright reiterated Buy at $18 in late September, and earlier initiations from Jones Trading, Clear Street and B. Riley sit between $20 and $33. The consensus is Buy across all ten covering analysts, with a mean target of $22.10. The gap between that mean and the current share price is wide enough to raise a practical question: the stock has sold off 9% over the past month even as the analyst community has been adding coverage. The Street's conviction and the tape's direction are pulling in opposite directions.
That divergence is sharpest in the options market. The put/call ratio has dropped to 0.47, nearly 2.5 standard deviations below its 20-day average of 0.53. That reading is the most call-heavy it has been over the past year, with the 52-week low for the PCR sitting at 0.18 and the high at 0.73. The shift in recent weeks is stark: through most of September the PCR was running above 0.55, a defensive tilt. Now it has flipped sharply toward calls even as the stock has continued to fall. Options traders are positioning for a bounce, or at minimum a re-rating around the November 5 earnings date, which is now 22 days away.
Short interest, which was the lead angle in last week's note, tells a more stable story this week. The short position dipped slightly to 18.0% of the free float, down from 18.4% last Friday. That is still deeply elevated and places AMPX in the 6th percentile for short score rank, meaning almost every name in its sector carries less short pressure. The ORTEX short score has eased marginally to 65.8 from a recent high above 67, but the direction of travel is small. What has changed more noticeably is the borrow market: availability has tightened from around 191% a week ago to 171% now, meaning lenders still hold well over one share available for every share currently borrowed, but the pool is shrinking. Cost to borrow remains negligible at 0.46%. Shorts are entrenched but not being squeezed.
The ownership picture adds context to why the stock may be struggling despite bullish analyst coverage. Insider activity through late August showed the CEO, CTO and a director all selling open-market shares at prices around $10, a level the stock has since broken below. Net insider selling over the trailing 90 days reached roughly $3.7 million. None of that activity was flagged as occurring under a pre-arranged 10b5-1 plan, which makes it more directional than routine. BlackRock has been adding, filing an updated 13G at 7.4% of the class in July, up from 5.8% previously. But several other holders, including SAIF Partners and The Vanguard Group, have both let their positions drop below the 5% reporting threshold without a further filing, a quiet exit that the 13D/G register captures only in hindsight.
Valuation multiples have been compressing with the share price. The PE ratio has fallen roughly 27% over 30 days to around 134x, and EV/EBITDA has pulled back by about 11% to near 78x over the same period. Those are still very demanding multiples for a company still reporting operating losses, even as the bear case acknowledges that the quarterly loss narrowed to $6.8 million from $12.9 million in the prior period. The bull case rests on a long runway: 93 SiCore customers, positive margin projections from 2026, and a 2036 revenue target of $3.2 billion that requires years of execution. The EPS momentum factor scores are striking in both directions. The 30-day and 90-day EPS momentum ranks are at the 98th and 100th percentiles respectively, meaning forward estimates have been rising sharply. But the current profitability metrics remain deeply negative, and the short score rank of 6 reflects how many bears remain.
Peers have had a rough week too. STEM fell 16% on the week and ENVX dropped 7%. SES bucked the trend sharply with a 27% weekly gain, though the two stocks share only modest correlation. The sector-wide pressure makes it harder to read AMPX's own decline as stock-specific. What will separate the stories is November 5, when the next earnings print will test whether the narrowing losses and customer count are tracking fast enough to justify any part of the analyst community's targets.
See the live data behind this article on ORTEX.
Open AMPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
